Alder Bio and its yeast-produced antibodies take in $40M
Alder Biopharmaceuticals, a Bothell, Wash., developer of antibody drugs, raised $40 million in a third funding round. Investors included Delphi Ventures, TPG Biotech, Sevin Rosen Funds, Ventures West, H.I.G. Ventures, and WRF Capital.
Alder develops antibody-based drugs for inflammation and autoimmune disease. The company’s lead candidate, ALD518, is currently in clinical trials as a treatment for rheumatoid arthritis and cancer, although neither Alder’s Web site nor its statement disclose when the drug began human tests.
Alder’s work… Continue Reading
Nuon Therapeutics: A transplanted company tries to teach an old drug new tricks
At a first glance, San Francisco’s Nuon Therapeutics looks like any other specialty-pharmaceutical company that aims to pick up cast-off or failed drugs and try to squeeze some new life out of them. That sort of business model is frequently dull as dishwater, however lucrative it may turn out to be for the investors involved.
Unlike many specialty pharmas, however, Nuon — a recently renamed biotech transplant from Australia that just raised $5 million in… Continue Reading